BIOTRON LIMITED (ASX:BIT) - Ann: Appointment of Chief Medical Officer, 46287774, page-152 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Australia's largest stock trading and investment forum Australia's #1 stock forum

BIT

Click for more information

0.00%

1.7¢ biotron limited

First 152 Last

Share
Profile

Follow
della

116 Posts.

2

04/08/20

12:01

Post #: 46287774
Share

Originally posted by Batmansdaughter: ↑

I've been meaning to mention that I think the appointment of Dr Becker is the most significant news since the 2018 HIV results were released. As MM states, his appointment comes at this critical stage of development. I'm assuming she's referring to the HIV stage where the new results demonstrating how 225 actually works, are what are crucial to further advancement, and his appointment will be to drive a clinical/business alignment with a third party. After all, it is about at this stage of any drug development that a well connected medical expert who can talk the talk is necessary to open the way for progress. In my mind, his appointment speaks volumes with where Biotron is going with HIV.

But we can't not consider that such a person will be equally required if the pending SARS2 results return positive and an antiviral opportunity arises.
In fact, his appointment will even be more crucial if this does occur, and I suggest that any antiviral development for C19 is more likely to occur in the US. However, until results are released, we just don't know what is going on, other than the positive affirmation made in the recent quarterly. But once again, if results are positive, Dr. Becker will have his hands very full.

My own reading and research are still indicating that there is more likelihood of ion channeling inhibition is going to play a major role in curing C19, and that Biotron is as good as anyone in making the necessary breakthrough. There is much research occurring now that is focusing on E and for good reason. But we all know that here. I'll share my findings in good time (if BIT doesn't beat me to it).

Nice price action today. I placed another small bid at .098, yet to be hit.

Expand

BMD you would have seen this latest from your Saudi's?

https://www.drugtargetreview.com/news/66241/near-identical-protein-on-sars-and-covid-19-could-be-targeted-by-fda-approved-drugs/

Link from that article BIT gets mention.

https://www.frontiersin.org/articles/10.3389/fcimb.2020.00405/full

Another compound BIT225 also appear to be a potent inhibitor of IC activity in p7 viroporins (Behmard et al., 2018), see reference (Jalily et al., 2020) for more options.

Originally posted by Batmansdaughter: ↑

I've been meaning to mention that I think the appointment of Dr Becker is the most significant news since the 2018 HIV results were released. As MM states, his appointment comes at this critical stage of development. I'm assuming she's referring to the HIV stage where the new results demonstrating how 225 actually works, are what are crucial to further advancement, and his appointment will be to drive a clinical/business alignment with a third party. After all, it is about at this stage of any drug development that a well connected medical expert who can talk the talk is necessary to open the way for progress. In my mind, his appointment speaks volumes with where Biotron is going with HIV.

But we can't not consider that such a person will be equally required if the pending SARS2 results return positive and an antiviral opportunity arises.
In fact, his appointment will even be more crucial if this does occur, and I suggest that any antiviral development for C19 is more likely to occur in the US. However, until results are released, we just don't know what is going on, other than the positive affirmation made in the recent quarterly. But once again, if results are positive, Dr. Becker will have his hands very full.

My own reading and research are still indicating that there is more likelihood of ion channeling inhibition is going to play a major role in curing C19, and that Biotron is as good as anyone in making the necessary breakthrough. There is much research occurring now that is focusing on E and for good reason. But we all know that here. I'll share my findings in good time (if BIT doesn't beat me to it).

Nice price action today. I placed another small bid at .098, yet to be hit.

Expand

Originally posted by Batmansdaughter: ↑

I've been meaning to mention that I think the appointment of Dr Becker is the most significant news since the 2018 HIV results were released. As MM states, his appointment comes at this critical stage of development. I'm assuming she's referring to the HIV stage where the new results demonstrating how 225 actually works, are what are crucial to further advancement, and his appointment will be to drive a clinical/business alignment with a third party. After all, it is about at this stage of any drug development that a well connected medical expert who can talk the talk is necessary to open the way for progress. In my mind, his appointment speaks volumes with where Biotron is going with HIV.

But we can't not consider that such a person will be equally required if the pending SARS2 results return positive and an antiviral opportunity arises.
In fact, his appointment will even be more crucial if this does occur, and I suggest that any antiviral development for C19 is more likely to occur in the US. However, until results are released, we just don't know what is going on, other than the positive affirmation made in the recent quarterly. But once again, if results are positive, Dr. Becker will have his hands very full.

My own reading and research are still indicating that there is more likelihood of ion channeling inhibition is going to play a major role in curing C19, and that Biotron is as good as anyone in making the necessary breakthrough. There is much research occurring now that is focusing on E and for good reason. But we all know that here. I'll share my findings in good time (if BIT doesn't beat me to it).

Nice price action today. I placed another small bid at .098, yet to be hit.

Expand

Originally posted by Batmansdaughter: ↑

I've been meaning to mention that I think the appointment of Dr Becker is the most significant news since the 2018 HIV results were released. As MM states, his appointment comes at this critical stage of development. I'm assuming she's referring to the HIV stage where the new results demonstrating how 225 actually works, are what are crucial to further advancement, and his appointment will be to drive a clinical/business alignment with a third party. After all, it is about at this stage of any drug development that a well connected medical expert who can talk the talk is necessary to open the way for progress. In my mind, his appointment speaks volumes with where Biotron is going with HIV.

But we can't not consider that such a person will be equally required if the pending SARS2 results return positive and an antiviral opportunity arises.
In fact, his appointment will even be more crucial if this does occur, and I suggest that any antiviral development for C19 is more likely to occur in the US. However, until results are released, we just don't know what is going on, other than the positive affirmation made in the recent quarterly. But once again, if results are positive, Dr. Becker will have his hands very full.

My own reading and research are still indicating that there is more likelihood of ion channeling inhibition is going to play a major role in curing C19, and that Biotron is as good as anyone in making the necessary breakthrough. There is much research occurring now that is focusing on E and for good reason. But we all know that here. I'll share my findings in good time (if BIT doesn't beat me to it).

Nice price action today. I placed another small bid at .098, yet to be hit.

Expand

Originally posted by Batmansdaughter: ↑

I've been meaning to mention that I think the appointment of Dr Becker is the most significant news since the 2018 HIV results were released. As MM states, his appointment comes at this critical stage of development. I'm assuming she's referring to the HIV stage where the new results demonstrating how 225 actually works, are what are crucial to further advancement, and his appointment will be to drive a clinical/business alignment with a third party. After all, it is about at this stage of any drug development that a well connected medical expert who can talk the talk is necessary to open the way for progress. In my mind, his appointment speaks volumes with where Biotron is going with HIV.

But we can't not consider that such a person will be equally required if the pending SARS2 results return positive and an antiviral opportunity arises.
In fact, his appointment will even be more crucial if this does occur, and I suggest that any antiviral development for C19 is more likely to occur in the US. However, until results are released, we just don't know what is going on, other than the positive affirmation made in the recent quarterly. But once again, if results are positive, Dr. Becker will have his hands very full.

My own reading and research are still indicating that there is more likelihood of ion channeling inhibition is going to play a major role in curing C19, and that Biotron is as good as anyone in making the necessary breakthrough. There is much research occurring now that is focusing on E and for good reason. But we all know that here. I'll share my findings in good time (if BIT doesn't beat me to it).

Nice price action today. I placed another small bid at .098, yet to be hit.

Expand

Originally posted by Batmansdaughter: ↑

I've been meaning to mention that I think the appointment of Dr Becker is the most significant news since the 2018 HIV results were released. As MM states, his appointment comes at this critical stage of development. I'm assuming she's referring to the HIV stage where the new results demonstrating how 225 actually works, are what are crucial to further advancement, and his appointment will be to drive a clinical/business alignment with a third party. After all, it is about at this stage of any drug development that a well connected medical expert who can talk the talk is necessary to open the way for progress. In my mind, his appointment speaks volumes with where Biotron is going with HIV.

But we can't not consider that such a person will be equally required if the pending SARS2 results return positive and an antiviral opportunity arises.
In fact, his appointment will even be more crucial if this does occur, and I suggest that any antiviral development for C19 is more likely to occur in the US. However, until results are released, we just don't know what is going on, other than the positive affirmation made in the recent quarterly. But once again, if results are positive, Dr. Becker will have his hands very full.

My own reading and research are still indicating that there is more likelihood of ion channeling inhibition is going to play a major role in curing C19, and that Biotron is as good as anyone in making the necessary breakthrough. There is much research occurring now that is focusing on E and for good reason. But we all know that here. I'll share my findings in good time (if BIT doesn't beat me to it).

Nice price action today. I placed another small bid at .098, yet to be hit.

Expand

BIT Price at posting: 10.5¢ Sentiment: Buy Disclosure: Not Held
16 Upvote

2 Great analysis

Reply

Top Stories

CBL

Control Bionics expands into UK and Irish markets with NeuroNode device

CNB

Carnaby Resources hits copper at Mohawk, QLD

YAL

Yancoal makes it into the ASX200 in latest S&P rebalance

GDC

Global Data Centres not clear on future operations after AirTrunk sale payout

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

There are more pages in this discussion • 15 more messages in this thread...

First 152 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 1.7¢		Change 0.000(0.00%)		Mkt cap ! $15.33M

Open	High	Low	Value	Volume
1.7¢	1.9¢	1.7¢	$60.58K	3.424M

Buyers (Bids)

No.	Vol.	Price($)
11	593549	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	32352	1

View Market Depth

No.	Vol.	Price($)
10	566484	0.017
17	1713691	0.016
13	1709333	0.015
1	250000	0.014
2	580000	0.013

Price($)	Vol.	No.
0.018	32352	1
0.019	204328	3
0.020	849211	9
0.021	60000	1
0.022	826611	3

Last trade - 16.10pm 09/09/2024 (20 minute delay)

BIT (ASX) Chart